Regulatory T-Cell (Tregs) Therapies Market, 2021-2035

Research and development agreements emerged as the most popular type of partnership models adopted by industry stakeholders (34%),

Roots Analysis has done a detailed study on “Global Regulatory T-Cell (Tregs) Therapies Market, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

Key Inclusions

  • A detailed overview of the current market landscape of Treg cell therapies, along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders, dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates). 

 

  • An in-depth analysis of completed, ongoing and planned clinical studies of various Treg cell therapies, based on various relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial recruitment status, study design, average time taken, target patient segment, gender of enrolled patients, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted) and regional distribution of trials.

 

  • An analysis of the recent partnerships inked between various players engaged in this domain, during the period 2015-2021 (till August). Additionally, it includes a brief description of various types of partnership models (such as RD agreements, product development and commercialization agreements, licensing agreements, acquisitions, clinical trial agreements, and manufacturing agreements) that have been adopted by stakeholders, during the given period.

 

  • A detailed analysis of various investments, such as seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing that were undertaken by companies engaged in this domain, during the period 2014-2021 (till August).

 

  • Detailed profiles of clinical stage Treg cell therapies (phase I/II or above); each profile features an overview of the therapy, along with information on clinical trials and its endpoints, dosage regimen, key insights and estimated sales revenues (if available).

 

  • A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.

 

  • Elaborate profiles of prominent players engaged in the development of Treg cell therapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio and recent developments.

 

  • It features an elaborate discussion on the future commercial opportunity offered by Treg cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of Product
  • Tregs
  • Interleukins
  • Small molecules

 

  • Target Indication
  • Crohn’s Disease
  • Bipolar Disorder
  • Allergic Rhinoconjunctivitis
  • COVID 19
  • Diabetes Mellitus
  • Systemic Lupus Erythematosus
  • Alzheimer’s Disease
  • Graft Vs Host Disease

 

  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific 

 

 

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development.

 

 

To request sample pages, please visit this https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html

 

Key Questions Answered

  • What are the prevalent RD trends related to Treg cell therapies?
  • Which are the key therapeutic areas currently being targeted by Treg cell therapies?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of Treg cell therapies?
  • What are the key geographies where research focused on Treg cell therapies is being conducted?
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html

You may also be interested in the following reports : 

  1. Digital Health Market : Focus on Digital Therapeutics (2nd Edition), 2020-2030
  2. Deep Learning Market: Focus on Medical Image Processing, 2020-2030
  3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
  4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030

 

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/